Inhibrx Inc
NASDAQ:INBX
Inhibrx Inc
Pre-Tax Income
Inhibrx Inc
Pre-Tax Income Peer Comparison
Competitive Pre-Tax Income Analysis
Latest Figures & CAGR of Competitors
Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Inhibrx Inc
NASDAQ:INBX
|
Pre-Tax Income
-$239.7m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Pre-Tax Income
$6.3B
|
CAGR 3-Years
23%
|
CAGR 5-Years
4%
|
CAGR 10-Years
2%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Pre-Tax Income
$1.1B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-16%
|
|
Amgen Inc
NASDAQ:AMGN
|
Pre-Tax Income
$4.3B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-2%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Pre-Tax Income
$4.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Pre-Tax Income
$4B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
10%
|
CAGR 10-Years
18%
|
See Also
What is Inhibrx Inc's Pre-Tax Income?
Pre-Tax Income
-239.7m
USD
Based on the financial report for Dec 31, 2023, Inhibrx Inc's Pre-Tax Income amounts to -239.7m USD.
What is Inhibrx Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-51%
Over the last year, the Pre-Tax Income growth was -65%. The average annual Pre-Tax Income growth rates for Inhibrx Inc have been -47% over the past three years , -51% over the past five years .